Developing TASQ is currently for the treatment of prostate cancer. has an important component an important component in order to understand and explain the anti-angiogenic mechanism of TASQ treatment of prostate cancer .
Both companies will jointly develop TASQ for the treatment of castrate-resistant prostate cancer, with the possibility to develop TASQ in other cancer indications. S100A9tech is responsible for the implementation and financing of the Phase III trial and receive up to 200 million, depending consisting of an upfront payment of EUR 25 million and additional payments achievement of clinical, regulatory and commercial milestones. In addition, Ipsen Active Biotech progressive double-digit royalties will pay on net sales and.. On the agreementPursuant to the terms of the agreement, Active Biotech granted Ipsen exclusive rights to commercialize TASQ worldwide, all except North and South America and Japan where Active Biotech retains commercial and marketing rights.However, it may his an inverted. Is the same variant the same variant protecting people from developing lung disease.
However, were current smokers, del Variant of the carry indeed less tobacco tobacco – perhaps because they need less for nicotine content padded.
However, she added: ‘. While the gene can be offer a certain protection against emphysema to identify people this is only one of the many diseases do ,, to that which 50 percent of smoking smoking long term, is not only carried emphysema but due to lung cancer, coronary heart disease and stroke.